



2024/8/21

產業類別	生技
投資建議	買進 
收盤價	目標價
NT\$ 102.00	NT\$ 126.00

本次報告：法說會

交易資料

潛在報酬率 (%)	23.53
52 週還原收盤價區間 (NT\$)	60.24-108.57
市值 (NT\$百萬元)	9840
市值 (US\$百萬元)	308
流通在外股數 (百萬股)	97.00
董監持股 (%)	8.76
外資持股 (%)	15.30
投信持股 (%)	0.00
融資使用率 (%)	14.53

財務資料

	2023
股東權益 (NT\$百萬元)	3,498
ROA (%)	6.39
ROE (%)	11.84
淨負債比率 (%)	43.99

公司簡介

聯合為一製造人工關節與膝關節之醫療器材廠商，公司營運策略上以發展自有品牌 United 為主，2Q24 年各區域營收占比，歐洲 31%，台灣 24%，美國 17%，日本 6%，其他國際經銷市場 9%，中國 4%，併購之冠亞生技營收佔比為 10%。

主要客戶：醫院

主要競爭對手：嬌生、Stryker、Zimmer

陳奕均 fion.chen@sinopac.com

聯合 (4129 TT)

市場揮灑空間仍大


永豐觀點

4Q 旺季將臨，營收表現可望再上一階外，中長期在既有客戶新增需求與新醫院、新市場持續加入下，營運穩健向上無虞。

投資評價與建議


投資建議買進：(1) 短期臨近 4Q 至 1Q 過年前骨科年會及冬季骨科手術旺季，預期營收水位將再上一階；(2) 老年化社會支撐全球骨科市場剛性需求持續成長趨勢明確，對聯合骨科而言，隨多年產品布局完整、有效搶食市佔加上醫生認同度提高下，營收堆疊效果持續顯現，由於公司在全球市場市佔率<1%，拓展空間仍大，研究處認為隨既有客戶新增需求與新醫院、新市場持續加入下，中長期營運穩健向上應無虞，維持買進，目標價考量時序進入下半年，故以 2025 年進行評價，重新設定目標價由 124 元調升至 126 元(20 X 2025 EPS)。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

營運現況與分析

公司簡介：聯合為一製造人工髖關節與膝關節之醫療器材廠商，公司營運策略上以發展自有品牌 United 為主，2Q24 年各區域營收占比，歐洲 31%，台灣 24%，美國 17%，日本 6%，其他國際經銷市場 9%，中國 4%，併購之冠亞生技營收佔比為 10%，公司主要客戶為醫院，競爭對手為嬌生、Stryker、Zimmer 等。

2Q 稅後 EPS 1.06 元，較預期低：聯合 2Q 營收 11.4 億元(+7%QoQ、+22.2%YoY)，毛利率 77.4%，稅後淨利 1.02 億元(+9.1%QoQ、+19.9%YoY)，稅後 EPS 1.06 元，表現低於預期，主因費用率 63.6%，高於預期之 62.4%，加上稅率 30%，也較預期 25% 高所致。

重點市場持續成長：就各市場營運表現：

1. 台灣市場：2024 年 1-7 月營收 6.21 億元(+22%YoY)，營收持續成長除骨科需求每年自然成長率約 3-5% 外，公司也持續侵蝕第一大廠市場份額，由於市占率還有提升空間，預期台灣市場將可維持雙位數成長；
2. 國際經銷市場：2024 年 1-7 月營收 2.48 億元(+1%YoY)，營收動能呈持平狀，主因除考量部分國家匯率及政治等因素，出貨態度較保守外，另銷售區域上，也將烏克蘭、希臘等地由國際經銷市場劃分至歐盟地區；
3. 中國市場：2024 年 1-7 月營收 0.85 億元(-3%YoY)，聯合在中國市場銷售模式有二，一為台灣製造之產品出口至中國，此部分於合併營收中認列，另一為合資公司聯合新華在地生產國製產品，此部分屬業外投資收益，由於中國二次國採決標，聯合及當地國產品牌均得標，隨各省逐步進行採購下，預計 4Q 起有助海外虧損幅度快速縮小，且 2025 年亦有機會轉盈；
4. 美國市場：2024 年 1-7 月營收 4.66 億元(+33%YoY)，隨與骨科 KOL 醫生合作開發產品、有效提高品牌認同度下，聯合美國市場營收持續成長，由於相較國際品牌大廠，公司在美國市場市佔率仍低、拓展空間大，加上 2025 年預計有 3-4 項上市下，強勁成長動能應可延續；
5. 歐洲市場：2024 年 1-7 月營收 8.2 億元(+23%YoY)，歐洲市場中，法國為聯合主力市場所在，目前營收占比近 80%，由於聯合骨科產品在法國市場已佔有一定市占，故在既有醫院使用增加且陸續爭取新醫院採用下，法國市場營運表現穩健外，公司也積極開發英國、比利時等歐洲其他地區下，預期整體歐洲市場營收將維持雙位數成長；
6. 日本市場：2024 年 1-7 月營收 1.44 億元(+41%YoY)，因日本市場基期尚低，且市場拓展空間仍大下，預期營收可維持快速成長表現。

財務預估：預估聯合骨科 2024 年營收 47.1 億元(+19.7%YoY，原估 47.5 億元)，毛利率 77.7%，稅後淨利 4.77 億元(+19.7%YoY)，稅後 EPS 為 4.94 元(原估 5.64 元)。2025 年營收 54.9 億元(+16.7%YoY)，毛利率 77.2%，稅後淨利 6.09 億元(+27.5%YoY)，稅後 EPS 6.32 元。

附表一：當年度損益表

單位：百萬元	24Q1	24Q2	24Q3F	24Q4F	2024F
營業收入	1,066	1,141	1,130	1,368	4,705
營業毛利	832	883	874	1,067	3,655
營業利益	125	157	164	210	655
稅前淨利	126	149	167	212	653
稅後純益	94	102	124	157	477
稅後 EPS (元)	0.97	1.06	1.28	1.63	4.94
營收 QoQ 成長率	-6.02	7.02	-0.88	21.06	--
營收 YoY 成長率	14.84	22.22	20.99	20.63	19.75
毛利率	78.06	77.44	77.35	78.00	77.68
營益率	11.72	13.77	14.51	15.35	13.92
稅後純益率	8.82	9.14	10.97	11.48	10.14

資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	2,571	3,169	3,930	4,705	5,490
%變動率	9.76	23.25	24.02	19.72	16.68
營業毛利	1,841	2,363	3,036	3,655	4,239
毛利率 (%)	71.62	74.57	77.26	77.68	77.21
營業淨利	161	342	543	655	819
稅前淨利	75	303	509	653	820
%變動率	-31.66	306.23	68.05	28.29	25.57
稅後純益	52	222	384	477	610
%變動率	-48.67	323.82	73.43	24.22	27.88
稅後 EPS * (元)	0.37	2.84	4.50	4.94	6.32
市調 EPS * (元)	-0.21	2.22	3.93	5.25	--
PER (x)	275.68	35.92	22.67	20.65	16.14
PBR (x)	3.30	3.00	2.70	2.83	2.66
每股淨值 * (元)	30.90	33.99	37.81	36.03	38.39
每股股利 (元)	0.00	2.28	4.00	4	--
殖利率 (%)	--	5.12	4.89	3.92	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
----	---	---

香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288
----	---

上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220
----	---

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Disclosures for U.S. Persons**

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.